{"entity":{"id":"calgb-80405","kind":"trial","name":"CALGB/SWOG 80405","aka":[],"tldr":"The head-to-head test of the two biological drugs given first for bowel cancer. Overall they tied, and only the later analysis by which side of the colon the tumour started separated them.","summary":"CALGB/SWOG 80405 randomised 1,137 patients with KRAS wild-type untreated advanced colorectal cancer to cetuximab (578) or bevacizumab (559) with mFOLFOX6 or FOLFIRI chosen by the treating team. Median overall survival was 30.0 against 29.0 months (stratified hazard ratio 0.88, 95% CI 0.77 to 1.01, p=0.08), progression-free survival 10.5 against 10.6 months and response 59.6 against 55.2 percent. The trial therefore did not choose between the classes. Its secondary analyses by primary tumour side, published alongside those of FIRE-3, showed the anti-EGFR advantage is confined to left-sided tumours and that right-sided tumours do worse with cetuximab, the observation PARADIGM later confirmed prospectively.","status":"mixed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT00265850","url":"https://clinicaltrials.gov/study/NCT00265850"},{"label":"CALGB/SWOG 80405: first-line chemotherapy with cetuximab or bevacizumab in KRAS wild-type advanced colorectal cancer (JAMA 2017)","url":"https://doi.org/10.1001/jama.2017.7105"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["monoclonal-antibody","antiangiogenic","cytotoxic-chemotherapy"],"targets":["egfr","vegf","kras"],"drugs":["cetuximab","bevacizumab","folfox","folfiri"],"companies":["alliance-oncology","swog"],"institutions":[],"pathways":[],"terms":["sidedness"],"trials":["crystal-fire3","paradigm"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00265850","phase":"3","setting":"KRAS wild-type untreated advanced or metastatic colorectal cancer: cetuximab against bevacizumab, each added to physician-chosen mFOLFOX6 or FOLFIRI","sponsor":"Alliance for Clinical Trials in Oncology","result":"Median overall survival 30.0 with cetuximab against 29.0 months with bevacizumab: no significant difference.","yearReported":2017,"enrolled":1137,"enrolledBasis":"analysed","enrolledNote":"The registry lists 2,334 enrolled across the whole trial including the KRAS-unselected period before the protocol amendment; 1,137 KRAS wild-type patients were randomised and analysed in the JAMA report.","outcomes":[{"endpoint":"Overall survival","primary":true,"unit":"months","arms":[{"name":"Chemotherapy plus cetuximab","n":578,"value":30},{"name":"Chemotherapy plus bevacizumab","n":559,"value":29}],"hr":0.88,"ci":[0.77,1.01],"p":"0.08","source":"https://doi.org/10.1001/jama.2017.7105"}],"replication":"FIRE-3 found an overall survival advantage for cetuximab (28.7 against 25.0 months); PARADIGM confirmed the left-sided advantage prospectively."},"route":"/trials/calgb-80405/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"}],"company":[{"id":"alliance-oncology","kind":"company","name":"Alliance for Clinical Trials in Oncology","route":"/companies/alliance-oncology/"},{"id":"swog","kind":"company","name":"SWOG Cancer Research Network","route":"/companies/swog/"}],"term":[{"id":"sidedness","kind":"term","name":"Sidedness (left vs right colon)","route":"/terms/sidedness/"}],"trial":[{"id":"crystal-fire3","kind":"trial","name":"CRYSTAL & FIRE-3","route":"/trials/crystal-fire3/"},{"id":"keynote-177","kind":"trial","name":"KEYNOTE-177","route":"/trials/keynote-177/"},{"id":"paradigm","kind":"trial","name":"PARADIGM","route":"/trials/paradigm/"}],"biomarker":[{"id":"ras-wild-type","kind":"biomarker","name":"RAS wild-type (extended KRAS and NRAS testing)","route":"/biomarkers/ras-wild-type/"}]}}